Drug Profile
APP 201533
Latest Information Update: 30 Aug 2002
Price :
$50
*
At a glance
- Originator Unknown
- Developer Novartis
- Class Cardiotonics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 25 Mar 1996 Discontinued-unspecified phase for Heart Failure